Compounds > k00135
Page last updated: 2024-11-11

k00135

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5459373
CHEMBL ID200528
SCHEMBL ID2950857
MeSH IDM000612684

Synonyms (19)

Synonym
imidazopyridazin 1
1-(3-{6-[(cyclopropylmethyl)amino]imidazo[1,2-b]pyridazin-3-yl}phenyl)ethanone
K00135 ,
DB04715
1-(3-{6-[(cyclopropylmethyl)amino]imidazo[1,2-a]pyridazin-3-yl}phenyl)ethan-1-one
chembl200528 ,
imidazol[1,2-b]pyridazine 1
bdbm11835
cancer res 676916 compound k00135
1-[3-[6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]ethanone
2C3I
SCHEMBL2950857
SR-01000383555-1
sr-01000383555
1-(3-(6-(cyclopropylmethylamino)imidazo[1,2-b]pyridazin-3-yl)phenyl)ethanone
Q27095456
869650-21-5
1-[3-[6-[(cyclopropylmethyl)amino]imidazo[1,2-b]pyridazin-3-yl]phenyl]-ethanone
AKOS040748648
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase pim-1Homo sapiens (human)IC50 (µMol)0.51050.00040.887110.0000AID1799286; AID257081; AID351984
Serine/threonine-protein kinase pim-2Homo sapiens (human)IC50 (µMol)0.96000.00470.52145.1000AID1799286
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Serine/threonine-protein kinase pim-1Homo sapiens (human)Kd0.02500.00101.139319.3160AID257082
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
G1/S transition of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein phosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of cell population proliferationSerine/threonine-protein kinase pim-2Homo sapiens (human)
apoptotic mitochondrial changesSerine/threonine-protein kinase pim-2Homo sapiens (human)
response to virusSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of autophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of macroautophagySerine/threonine-protein kinase pim-2Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionSerine/threonine-protein kinase pim-2Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-2Homo sapiens (human)
regulation of mitotic cell cycleSerine/threonine-protein kinase pim-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-2Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID257082Binding affinity to non phosphorylated PIM12005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID1722579Binding affinity to haspin (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID643937Growth inhibition of human MOLM13 cells after 48 hrs by WST-1 assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
AID1722594Binding affinity to RSK4B (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722588Binding affinity to CLK1 (H148 to I484 residues) (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722570Binding affinity to ACVR1B (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722585Binding affinity to PIM3 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722641Selective index, difference between deltaTm for recombinant wild type CLK1 (H148 to I484 residues) (unknown origin) expressed in Escherichia coli to deltaTm for recombinant CLK1 V324A mutant (unknown origin) expressed in Escherichia coli2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722595Binding affinity to RSK1B (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722576Binding affinity to BMPR2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722596Binding affinity to CSNK1E (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722580Binding affinity to CLK4 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID257080Inhibitory activity against PIM1 at 10 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID351984Inhibition of Pim1 assessed as [32P] incorporation preincubated for 15 mins before ATP substrate addition by coupled spectrophotometric assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
AID1722591Binding affinity to PIM2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722572Binding affinity to BMPR1B (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722584Binding affinity to PIM1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID257081Inhibitory activity against PIM12005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID1722578Binding affinity to ACTR2B (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722569Binding affinity to ACVRL1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID643936Growth inhibition of human RS4:11 cells after 48 hrs by WST-1 assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
AID643939Growth inhibition of human K562 cells after 48 hrs by WST-1 assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
AID1722642Selective index, difference between deltaTm for CLK3 A319V mutant (unknown origin) expressed in Escherichia coli to deltaTm for recombinant wild type CLK3 (R134 to T484 residues) (unknown origin) expressed in Escherichia coli2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722586Binding affinity to RIPK2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722581Binding affinity to AAK1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722577Binding affinity to ACVR1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722575Binding affinity to TGFBR2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722571Binding affinity to TGFBR1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722573Binding affinity to BMPR1A (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722589Binding affinity to CLK2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722582Binding affinity to GAK (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722574Binding affinity to ACTR2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722592Binding affinity to DRAK2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID643938Growth inhibition of human SEM cells after 48 hrs by WST-1 assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
AID257079Inhibitory activity against PIM1 at 1 uM2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID1722583Binding affinity to BIKE (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722587Binding affinity to DYRK2 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID643935Growth inhibition of human MV4-11 cells after 48 hrs by WST-1 assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.
AID1722568Binding affinity to JAK1 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722593Binding affinity to SgK085 (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID1722590Binding affinity to GSK3B (unknown origin) assessed as change in melting temperature at 10 uM incubated for 10 mins using SYPRO orange dye by RT-PCR-based fluorescence assay2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2005Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase.
AID1799286Kinase Inhibition Assay from Article 10.1158/0008-5472.CAN-07-0320: \\Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.\\2007Cancer research, Jul-15, Volume: 67, Issue:14
Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bisindolylmaleimide i
bisindolylmaleimide I: a bis(indolyl)maleimide		2.0210
bisindolylmaleimide iv
[no description available]		2.0210indoles;
maleimides
ro 31-7549
Ro 31-7549: structure		2.0210
ro 31-8220
Ro 31-8220: a protein kinase C inhibitor		2.0210imidothiocarbamic ester;
indoles;
maleimides		EC 2.7.11.13 (protein kinase C) inhibitor
staurosporine
[no description available]		2.4820indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
5-iodotubercidin
7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase		2.2510organoiodine compound
3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone
3-cyano-4-phenyl-6-(3-bromo-6-hydroxyphenyl)-2-pyridone : A member of the class of pyridones that is 2-pyridone carrying cyano, phenyl and 3-bromo-6-hydroxyphenyl substituents at positions 3, 4 and 6 respectively		2.0510bromophenol;
nitrile;
pyridone
quercetin
[no description available]		2.02107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
biochanin a
[no description available]		2.02104'-methoxyisoflavones;
7-hydroxyisoflavones		antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		2.0210trihydroxyflavoneantineoplastic agent;
metabolite
luteolin
[no description available]		2.02103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
kaempferol
[no description available]		2.02107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
genistein
[no description available]		2.02107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
baicalein
[no description available]		2.0210trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.02107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
fisetin
[no description available]		2.02103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
myricetin
[no description available]		2.02107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
quercetagetin
quercetagetin: structure given in first source; inhibits aldose reductase in rat lens. quercetagetin : A hexahydroxyflavone that is flavone substituted by hydroxy groups at positions 3, 5, 6, 7, 3' and 4' respectively.		2.0510flavonols;
hexahydroxyflavone		antioxidant;
antiviral agent;
plant metabolite
ConditionIndicatedRelationship StrengthStudiesTrials